Immune Dysregulation Associated with Breast Cancer | ||||
| Journal of High Institute of Public Health | ||||
| Article 10, Volume 33, Issue 1, January 2003, Page 129-140 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jhiph.2003.200287 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mona H. El-Sayed1; Inas M. Aly2; Salwa N. Abou Rawash2 | ||||
| 1Department of Immunology, Medical Research Institute, Alexandria University, Egypt | ||||
| 2Department of Oncology, Medical Research Institute, Alexandria University, Egypt | ||||
| Abstract | ||||
| ICancer development depends not only on the tumor cells themselves, but also on the immune regulatory effects of various cells. In an attempt to further understand the prognostic significance of p53, apoptosis and sIL-2R in cancer breast, we have evaluated serum levels of p53 and sIL-2R in 15 breast cancer patients by enzyme linked immunoassay. While DNA fragmentation was assessed as a marker of apoptosis using photometric sandwich ELISA technique together with 10 healthy women as control. A significant increase in serum p53 [8.18±0.4u/ml] and apoptosis [1.56±0.32 u/ml] were recorded in cancer patients than in control [6.29±0.38 u/ml] and [0.114±0.009 u/ml] respectively. This increase was positively correlated with the stage of carcinoma. A significant increase in serum sIL-2R was also observed in patients [1156.74±176.27 u/ml] than in control subject [774.145±40.641 u/ml]. Our results revealed the presence of immune dysregulation in patients with breast cancer, and we suggest that serum sIL-2R level; p53 and apoptosis could be useful markers to identifying population of patients with poor prognosis and follow up the response to chemotherapy. | ||||
| Keywords | ||||
| Immune Dysregulation; Breast Cancer | ||||
|
Statistics Article View: 57 |
||||
